Absorbed dose simulation of meta-211At-astato-benzylguanidine using pharmacokinetics of 131I-MIBG and a novel dose conversion method, RAP
Absorbed dose simulation of meta-211At-astato-benzylguanidine using pharmacokinetics of 131I-MIBG and a novel dose conversion method, RAP
复制标题
DOI：
10.1007/s12149-020-01548-6
复制
发表时间：
2020-11-22
影响因子：
2.6
通讯作者：
Ishioka, Noriko S.
中科院分区：
文献类型：
--
作者：
Sakashita, Tetsuya;Watanabe, Shigeki;Ishioka, Noriko S.
目的利用已报道的神经母细胞瘤移植瘤模型的I-131-MIBG生物分布数据，采用两种剂量转换方法估算At-211-MABG的体内吸收剂量。此外，我们研究了不同的细胞系和时间限制的影响，使用其他两个works.Methods的数据，我们使用的Monte Carlo方法的框架，创建3200个虚拟实验数据集的活性浓度（kBq/g），以获得统计信息。时间活性浓度曲线的遗传算法的拟合方法。其基本方法是根据医用内照射剂量公式，将I-131的物理半衰期转换为At-211的物理半衰期，计算At-211-MABG的吸收剂量。结果虚拟实验表明，At-211-MABG和I-131-MIBG具有相似的初始活性浓度和生物组分，但基本方法不能模拟At-211-MABG的剂量。使用RAP方法从I-131-MIBG模拟的At-211-MABG剂量与从At-211-MABG模拟的At-211-MABG剂量一致，使得它们的框在箱形图中重叠。RAP方法适用于不同的细胞株，但很难从短期实验数据预测长期剂量。结论目前RAP剂量转换方法可以从I-131-MIBG的药代动力学数据估算At-211-MABG的吸收剂量，但存在一定的局限性。RAP方法适用于大量受试者的靶向核素治疗。
Objective We aimed to estimate in vivo At-211-labeled meta-benzylguanidine (At-211-MABG) absorbed doses by the two dose conversion methods, using I-131-MIBG biodistribution data from a previously reported neuroblastoma xenograft model. In addition, we examined the effects of different cell lines and time limitations using data from two other works.Methods We used the framework of the Monte Carlo method to create 3200 virtual experimental data sets of activity concentrations (kBq/g) to get the statistical information. Time activity concentration curves were produced using the fitting method of a genetic algorithm. The basic method was that absorbed doses of At-211-MABG were calculated based on the medical internal radiation dose formalism with the conversion of the physical half-life time of I-131 to that of At-211. We have further improved the basic method; that is, a novel dose conversion method, RAP (Ratio of Pharmacokinetics), using percent injected dose/g.Results Virtual experiments showed that At-211-MABG and I-131-MIBG had similar properties of initial activity concentrations and biological components, but the basic method did not simulate the At-211-MABG dose. Simulated At-211-MABG doses from I-131-MIBG using the RAP method were in agreement with those from At-211-MABG, so that their boxes overlapped in the box plots. The RAP method showed applicability to the different cell lines, but it was difficult to predict long-term doses from short-term experimental data.Conclusions The present RAP dose conversion method could estimate At-211-MABG absorbed doses from the pharmacokinetics of I-131-MIBG with some limitations. The RAP method would be applicable to a large number of subjects for targeted nuclide therapy.